AMDR Applauds Federal Court Decision to Bar Johnson & Johnson’s Biosense Webster Unit from Further Violation of Anti-Trust Laws in a Win for Hospitals, Patients, and the Environment
Yesterday Court Issued Final Injunction After Jury Finds that Biosense Webster’s Unlawful, Anti-Competitive Practices Forced Hospitals to Purchase More Costly, Wasteful Products [Washington, D.C. — August 28, 2025] — The Association of Medical Device Reprocessors (AMDR) announced that Judge James Selna of the U.S. District Court for the Central District of California has issued a
STATEMENT – Innovative Health Seeks Permanent Injunction Against Johnson & Johnson Medtech’s Biosense Webster Following Landmark Antitrust Win
Motion filed includes evidence and testimony presented at trial demonstrating the lengths Johnson & Johnson MedTech’s Biosense Webster went to “crush” reprocessor competitors June 20, 2025 FOR IMMEDIATE RELEASE [Note to Editors: The case information discussed in this statement is publicly accessible on PACER and is summarized from the following documents, which AMDR has highlighted
Triple Damages — $442M — Awarded to AMDR Member Innovative Health in Case Against Johnson & Johnson’s Biosense Webster Medical Technology Unit for Withholding Technical Support When Reprocessed Devices Were Used
[Washington, D.C. and Berlin, Germany / 5 June 2025] Today, Judge James V. Selna of the U.S. District Court for the Central District of California entered judgment in Innovative Health LLC v. Biosense Webster, Inc., tripling the jury’s May 16 award from $147 million to $442 million as required by federal and California antitrust statutes.
STATEMENT On $147M Verdict for AMDR Member Innovative Health Against Johnson & Johnson’s Biosense Webster Medical Technology Unit
[Washington, D.C. and Berlin, Germany / 18 May 2025] Friday’s unanimous verdict by a federal jury in Santa Ana, California for Innovative Health against Johnson & Johnson (NYSE: JNJ) is a victory for America’s hospitals, providers, patients, and the environment. The jury found that Biosense Webster violated federal and state antitrust laws by withholding clinical
